MX2020000583A - Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados. - Google Patents
Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados.Info
- Publication number
- MX2020000583A MX2020000583A MX2020000583A MX2020000583A MX2020000583A MX 2020000583 A MX2020000583 A MX 2020000583A MX 2020000583 A MX2020000583 A MX 2020000583A MX 2020000583 A MX2020000583 A MX 2020000583A MX 2020000583 A MX2020000583 A MX 2020000583A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- binding
- methods
- protein
- cell
- Prior art date
Links
- 230000027455 binding Effects 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000012636 effector Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 230000009149 molecular binding Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535107P | 2017-07-20 | 2017-07-20 | |
| US201762575820P | 2017-10-23 | 2017-10-23 | |
| US201862648072P | 2018-03-26 | 2018-03-26 | |
| PCT/EP2018/069850 WO2019016402A1 (en) | 2017-07-20 | 2018-07-20 | BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000583A true MX2020000583A (es) | 2020-09-10 |
Family
ID=63113484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000583A MX2020000583A (es) | 2017-07-20 | 2018-07-20 | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11725060B2 (OSRAM) |
| EP (1) | EP3655439A1 (OSRAM) |
| JP (1) | JP7369113B2 (OSRAM) |
| KR (1) | KR102649757B1 (OSRAM) |
| CN (1) | CN111148763B (OSRAM) |
| AU (1) | AU2018304585B2 (OSRAM) |
| BR (1) | BR112020001180A2 (OSRAM) |
| CA (1) | CA3070272A1 (OSRAM) |
| CO (1) | CO2020001654A2 (OSRAM) |
| IL (1) | IL272103B2 (OSRAM) |
| MX (1) | MX2020000583A (OSRAM) |
| NZ (1) | NZ761636A (OSRAM) |
| PH (1) | PH12020500137A1 (OSRAM) |
| SG (1) | SG11202000503QA (OSRAM) |
| WO (1) | WO2019016402A1 (OSRAM) |
| ZA (1) | ZA202000961B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017182672A1 (en) | 2016-04-22 | 2017-10-26 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
| CA3056542A1 (en) * | 2017-03-15 | 2018-09-20 | Oxford Biomedica (Uk) Limited | Method |
| BR112020001180A2 (pt) * | 2017-07-20 | 2020-09-08 | Aptevo Research And Development Llc | proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados |
| KR20200130723A (ko) | 2018-03-12 | 2020-11-19 | 젠맵 에이/에스 | 항체 |
| AU2020320349A1 (en) | 2019-07-26 | 2022-02-17 | Yuhan Corporation | Anti-EGFR/anti-4-1BB bispecific antibody and use thereof |
| JP7725446B2 (ja) * | 2019-07-26 | 2025-08-19 | ユハン コーポレーション | 抗ｈｅｒ２／抗４－１ｂｂ二重特異性抗体及びその使用 |
| US20220242962A1 (en) * | 2019-08-12 | 2022-08-04 | Aptevo Research And Development Llc | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
| EP4155319A4 (en) * | 2020-06-30 | 2024-06-12 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1BB BINDING PROTEIN AND ITS USE |
| EP4297786A4 (en) * | 2021-02-23 | 2025-01-22 | Pandion Operations, Inc. | PD-1 ANTIBODIES, POLYPEPTIDES AND USES THEREOF |
| EP4346890A4 (en) * | 2021-05-28 | 2025-07-09 | Xyone Therapeutics Inc | MULTI-SPECIFIC ANTIBODY CONSTRUCTS AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4615974A (en) | 1981-08-25 | 1986-10-07 | Celltech Limited | Yeast expression vectors |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
| US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| EP0184576B1 (en) | 1984-12-06 | 1990-06-27 | Fina Research S.A. | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
| AU5103293A (en) | 1992-09-14 | 1994-04-12 | Oklahoma State University | Immortalized cells and uses therefor |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
| US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| US5854039A (en) | 1996-07-17 | 1998-12-29 | Zymogenetics, Inc. | Transformation of pichia methanolica |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DE60040555D1 (de) * | 1999-11-18 | 2008-11-27 | Oxford Biomedica Ltd | Küle |
| JP2003524644A (ja) | 2000-02-01 | 2003-08-19 | タノックス インコーポレイテッド | Ｃｄ４０−結合性ａｐｃ−活性化分子 |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| EP1786469A2 (en) | 2004-09-10 | 2007-05-23 | Wyeth a Corporation of the State of Delaware | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8044178B2 (en) | 2006-03-10 | 2011-10-25 | Wyeth Llc | Anti-5T4 antibodies and uses thereof |
| AU2007257692B2 (en) | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| CN102171247A (zh) | 2008-07-02 | 2011-08-31 | 特鲁比昂药品公司 | TNF-α拮抗剂多靶点结合蛋白 |
| CN107056951A (zh) | 2008-10-02 | 2017-08-18 | 阿帕特夫研究和发展有限公司 | Cd86拮抗物多靶点结合蛋白 |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| NZ600820A (en) | 2009-12-29 | 2014-12-24 | Emergent Product Dev Seattle | Heterodimer binding proteins and uses thereof |
| PH12020550156A1 (en) | 2010-09-09 | 2024-01-15 | Pfizer | 4-1bb binding molecules |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| US20130058936A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2013041687A1 (en) * | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| CA2943943C (en) | 2014-04-07 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| ES3034398T3 (en) | 2014-08-28 | 2025-08-18 | Bioatla Inc | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| HUE048532T2 (hu) | 2015-01-08 | 2020-07-28 | BioNTech SE | Agonista TNF receptor kötõ ágensek |
| JP2018503399A (ja) | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| AU2016264649B2 (en) | 2015-05-20 | 2018-11-22 | Immunwork Inc. | Molecular constructs with targeting and effector elements and their applications |
| EP3988577A1 (en) | 2015-05-21 | 2022-04-27 | Alligator Bioscience AB | Anti-cd137 antibodies |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| WO2017182672A1 (en) | 2016-04-22 | 2017-10-26 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
| US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| BR112020001180A2 (pt) | 2017-07-20 | 2020-09-08 | Aptevo Research And Development Llc | proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados |
-
2018
- 2018-07-20 BR BR112020001180-0A patent/BR112020001180A2/pt unknown
- 2018-07-20 US US16/632,144 patent/US11725060B2/en active Active
- 2018-07-20 MX MX2020000583A patent/MX2020000583A/es unknown
- 2018-07-20 EP EP18750355.2A patent/EP3655439A1/en active Pending
- 2018-07-20 IL IL272103A patent/IL272103B2/en unknown
- 2018-07-20 KR KR1020207004833A patent/KR102649757B1/ko active Active
- 2018-07-20 US US16/041,309 patent/US10239949B2/en active Active
- 2018-07-20 CA CA3070272A patent/CA3070272A1/en active Pending
- 2018-07-20 WO PCT/EP2018/069850 patent/WO2019016402A1/en not_active Ceased
- 2018-07-20 CN CN201880060362.6A patent/CN111148763B/zh active Active
- 2018-07-20 JP JP2020503056A patent/JP7369113B2/ja active Active
- 2018-07-20 NZ NZ761636A patent/NZ761636A/en unknown
- 2018-07-20 AU AU2018304585A patent/AU2018304585B2/en active Active
- 2018-07-20 SG SG11202000503QA patent/SG11202000503QA/en unknown
-
2019
- 2019-02-21 US US16/281,440 patent/US11312786B2/en active Active
-
2020
- 2020-01-20 PH PH12020500137A patent/PH12020500137A1/en unknown
- 2020-02-13 CO CONC2020/0001654A patent/CO2020001654A2/es unknown
- 2020-02-14 ZA ZA2020/00961A patent/ZA202000961B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ761636A (en) | 2023-07-28 |
| SG11202000503QA (en) | 2020-02-27 |
| KR20200037288A (ko) | 2020-04-08 |
| US11725060B2 (en) | 2023-08-15 |
| IL272103A (en) | 2020-03-31 |
| AU2018304585B2 (en) | 2023-07-06 |
| US11312786B2 (en) | 2022-04-26 |
| US20190016816A1 (en) | 2019-01-17 |
| WO2019016402A1 (en) | 2019-01-24 |
| KR102649757B1 (ko) | 2024-03-21 |
| RU2020102289A (ru) | 2021-08-24 |
| RU2020102289A3 (OSRAM) | 2022-01-17 |
| EP3655439A1 (en) | 2020-05-27 |
| CA3070272A1 (en) | 2019-01-24 |
| PH12020500137A1 (en) | 2020-11-09 |
| IL272103B1 (en) | 2024-06-01 |
| BR112020001180A2 (pt) | 2020-09-08 |
| US20200223933A1 (en) | 2020-07-16 |
| AU2018304585A1 (en) | 2020-02-27 |
| JP2020530770A (ja) | 2020-10-29 |
| US10239949B2 (en) | 2019-03-26 |
| CN111148763A (zh) | 2020-05-12 |
| JP7369113B2 (ja) | 2023-10-25 |
| ZA202000961B (en) | 2024-06-26 |
| IL272103B2 (en) | 2024-10-01 |
| CO2020001654A2 (es) | 2020-08-10 |
| US20190382503A1 (en) | 2019-12-19 |
| CN111148763B (zh) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202000961B (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
| MX2022015847A (es) | Proteinas de union a cd123 y composiciones y metodos relacionados. | |
| PH12018500520A1 (en) | Cd3 binding polypeptides | |
| WO2016094873A3 (en) | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods | |
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
| EP4442709A3 (en) | Improved serum albumin binders | |
| EP4442708A3 (en) | Improved serum albumin binders | |
| WO2019056023A3 (en) | Claudin6 antibodies and methods of treating cancer | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| WO2017085172A3 (en) | Improved serum albumin binders | |
| MX2012012119A (es) | Produccion de proteinas heteromultimericas. | |
| NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
| EP4389226A3 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| MX355255B (es) | Variantes de fc y métodos para su producción. | |
| UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
| MX2021001418A (es) | Produccion de proteinas heteromultimericas usando celulas de mamifero. | |
| WO2018071822A8 (en) | ANTIBODIES BINDING TO THE ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF | |
| EP4269433A3 (en) | Tgf-beta-rii binding proteins | |
| EA201990773A1 (ru) | Cd123-связывающие белки и относящиеся к ним композиции и способы |